BCLI – Brainstorm Cell Therapeutics, Inc.

Float Short %

9.16

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.44

EPS Last/This Y

0.71

EPS This/Next Y

0.16

Price

0.58

Target Price

20.68

Analyst Recom

Performance Q

50.39

Relative Volume

Beta

0.14

Ticker: BCLI

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-13	BCLI	0.63	N/A	N/A	0
2025-11-14	BCLI	0.6136	N/A	N/A	0
2025-11-17	BCLI	0.68	N/A	N/A	0
2025-11-18	BCLI	0.593	N/A	N/A	0
2025-11-19	BCLI	0.65	N/A	N/A	0
2025-11-20	BCLI	0.635	N/A	N/A	0
2025-11-21	BCLI	0.6405	N/A	N/A	0
2025-11-24	BCLI	0.63	N/A	N/A	0
2025-11-25	BCLI	0.63	N/A	N/A	0
2025-11-26	BCLI	0.593	N/A	N/A	0
2025-12-01	BCLI	0.6198	N/A	N/A	0
2025-12-02	BCLI	0.63	N/A	N/A	0
2025-12-03	BCLI	0.6059	N/A	N/A	0
2025-12-04	BCLI	0.609	N/A	N/A	0
2025-12-05	BCLI	0.6	N/A	N/A	0
2025-12-08	BCLI	0.6	N/A	N/A	0
2025-12-09	BCLI	0.605	N/A	N/A	0
2025-12-10	BCLI	0.56	N/A	N/A	0
2025-12-11	BCLI	0.585	N/A	N/A	0
2025-12-12	BCLI	0.59	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-13	BCLI	0.64	45.0	-	-1.60
2025-11-14	BCLI	0.63	45.0	-	-1.60
2025-11-17	BCLI	0.61	45.0	-	-1.60
2025-11-18	BCLI	0.68	45.0	-	-1.60
2025-11-19	BCLI	0.68	45.0	-	-1.60
2025-11-20	BCLI	0.65	45.0	-	-1.60
2025-11-21	BCLI	0.63	45.0	-	-1.60
2025-11-24	BCLI	0.64	45.0	-	-1.60
2025-11-25	BCLI	0.63	45.0	-	-1.60
2025-11-26	BCLI	0.62	45.0	-	-1.60
2025-12-01	BCLI	0.64	45.0	-	-1.60
2025-12-02	BCLI	0.61	45.0	-	-1.60
2025-12-03	BCLI	0.61	45.0	-	-1.60
2025-12-04	BCLI	0.61	45.0	-	-1.60
2025-12-05	BCLI	0.61	45.0	-	-1.60
2025-12-08	BCLI	0.60	45.0	-	-1.60
2025-12-09	BCLI	0.60	45.0	-	-1.60
2025-12-10	BCLI	0.60	45.0	-	-1.60
2025-12-11	BCLI	0.56	45.0	-	-1.60
2025-12-12	BCLI	0.58	45.0	-	-1.60
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="BCLI" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.91

Avg. EPS Est. Current Quarter

-0.33

Avg. EPS Est. Next Quarter

-0.47

Insider Transactions

Institutional Transactions

Beta

0.14

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.5

Target Price

20.68

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-2.01

Average EPS Est. Cur. Y

-1.6

EPS Next Y. (Est.)

-1.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

114.1

Return on Equity vs Industry %

129.1

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

0.61

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”BCLI” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BCLI” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BCLI” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BCLI” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BCLI” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BCLI” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”BCLI” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

BrainStorm Cell Therapeutics In

Sector: Healthcare

Industry: Biotechnology

Employees: 23

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

stock quote shares BCLI – Brainstorm Cell Therapeutics, Inc. Stock Price stock today

news today BCLI – Brainstorm Cell Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BCLI – Brainstorm Cell Therapeutics, Inc. yahoo finance google finance

stock history BCLI – Brainstorm Cell Therapeutics, Inc. invest stock market

stock prices BCLI premarket after hours

ticker BCLI fair value insiders trading

BCLI – Brainstorm Cell Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BCLI

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y